TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35954612

Group type: EXPERIMENTAL
Intervention: Hedonic aroma (essential oils) during chemotherapy (inhalation during T1, T2, T3)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 112
Study: 33619780

Group type: EXPERIMENTAL
Intervention: Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate foam (Cal/BD foam)
Number of subjects: 3
Study: 32142039

Group type: EXPERIMENTAL
Intervention: IC-8 Group (monofocal 1-piece Tecnis Z B00 IOL in dominant eye and IC-8 IOL in nondominant eye)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Symfony Group (Tecnis Symfony IOL in both eyes)
Number of subjects: 38
Study: 34785366

Group type: EXPERIMENTAL
Intervention: anodal tDCS (a-tDCS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: sham tDCS (s-tDCS)
Number of subjects: 48
Study: 34376257

Group type: EXPERIMENTAL
Intervention: Integrated malaria prevention methods (including insecticide-treated nets, house screening, indoor residual spraying)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Integrated malaria prevention methods
Number of subjects: 31
Study: 36113498

Group type: COMPARATOR
Intervention: CRT (78 Gy in 39 fractions over 7.8 weeks or 62 Gy in 20 fractions over 4 weeks)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: SBRT (36.25 Gy in five fractions over 1-2 weeks)
Number of subjects: 874
Study: 33314699

Group type: EXPERIMENTAL
Intervention: ACPA-positive patients
Number of subjects: 606
Study: 33177798

Group type: EXPERIMENTAL
Intervention: SPMC ½ dose × 2
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: SPMC 1 dose × 2
Number of subjects: 78

Group type: COMPARATOR
Intervention: PEG
Number of subjects: 78
Study: 35666526

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy with standard care
Number of subjects: 408
Study: 35607733

Group type: EXPERIMENTAL
Intervention: Sequential injection of 1.5 mL of 0.5% hyperbaric bupivacaine with 15 μg of fentanyl followed by 1.5 mL of 0.5% isobaric bupivacaine (HIB group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3 mL of 0.5% hyperbaric bupivacaine mixed with 15 μg of fentanyl citrate (HB group)
Number of subjects: 50
Study: 33307206

Group type: EXPERIMENTAL
Intervention: Yoga program (12-week, 2x weekly/90-minute sessions)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Education control group (1x weekly/60-minute lectures)
Number of subjects: 57
Study: 32460577

Group type: EXPERIMENTAL
Intervention: TIM-1 levels (third tertile)
Number of subjects: 4591

Group type: EXPERIMENTAL
Intervention: Mendelian Randomization analysis
Number of subjects: 4591
Study: 35101266

Group type: EXPERIMENTAL
Intervention: Four-dose schedule (0–7–21–360)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Three-dose schedule (days 0–30–360)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Four-dose schedule (0–30–90–360)
Number of subjects: 150
Study: 34402161

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 35247147

Group type: EXPERIMENTAL
Intervention: Family support-based intervention via a mobile application by pharmacists
Number of subjects: 157

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study: 33558076

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 60
Study: 35172436

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) for 3 days (Group A, n=138)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (Group B, n=112)
Number of subjects: 250
Study: 32420337

Group type: EXPERIMENTAL
Intervention: Peer group-based training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care by nurse (Control)
Number of subjects: 60
Study: 35139802

Group type: EXPERIMENTAL
Intervention: Loss of resistance plus nerve stimulation (LOR + NS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Loss of resistance alone (LOR-alone)
Number of subjects: 100
Study: 33414239

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily for 16 weeks
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo twice daily for 16 weeks
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily for 12 months
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo twice daily for 12 months
Number of subjects: 346
Study: 35361556

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (12-month duration, delivered twice weekly for the first 12 weeks, then once weekly; included cardiovascular, strength, balance, and flexibility exercises)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no physical activity intervention)
Number of subjects: 102
Study: 35150494

Group type: EXPERIMENTAL
Intervention: Education during pregnancy and listening to classical music
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 198
Study: 32538577

Group type: EXPERIMENTAL
Intervention: Rigid-TTI group (N=150)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Non-rigid TTI group (N=150)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Non-TTI group (N=150)
Number of subjects: 450
Study: 37816915

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (3 W, 150 mJ, 20 Hz, 100 μs) after FM-SRP
Number of subjects: 60

Group type: COMPARATOR
Intervention: FM-SRP
Number of subjects: 60
Study: 33625584

Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 32716326

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (2% for 20 minutes at 1mA/min) combined with exercises (1 hour, three times a week for three months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (exercises only, same duration and frequency)
Number of subjects: 30
Study: 34580251

Group type: EXPERIMENTAL
Intervention: Percutaneous left atrial appendage occlusion (LAAO)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Oral anticoagulation (OAC) therapy
Number of subjects: 980
Study: 33899580

Group type: COMPARATOR
Intervention: fenobam
Number of subjects: 20
Study: 36158133

Group type: EXPERIMENTAL
Intervention: Precision health education guidance after ESWL treatment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (only informed of precautions after lithotripsy)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Complete compliance group (n = 64)
Number of subjects: 104
Study: 32951965

Group type: EXPERIMENTAL
Intervention: Group I (flap with graft; n=16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group II (flap without graft; n=16)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group III (flapless without graft; n=16)
Number of subjects: 48
Study: 32555026

Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Interval Training (HIIT) in addition to treatment as usual (n = 13)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Treatment as usual (n = 8)
Number of subjects: 21
Study: 32031041

Group type: EXPERIMENTAL
Intervention: Idealised smile images
Number of subjects: 132

Group type: COMPARATOR
Intervention: Neutral nature images (Control)
Number of subjects: 132
Study: 35216854

Group type: EXPERIMENTAL
Intervention: Scenario‐Tailored Opioid Messaging Program (STOMP)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Routine prescription education
Number of subjects: 503
Study: 33321461

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 35378230

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 158

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 158
Study: 33469648

Group type: EXPERIMENTAL
Intervention: Unilateral FUS thalamotomy
Number of subjects: 35
Study: 32842819

Group type: EXPERIMENTAL
Intervention: Endobronchial valve therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up evaluation with CT-scan and/or bronchoscopy
Number of subjects: 0
Study: 36177850

Group type: EXPERIMENTAL
Intervention: Direct stenting (DS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional stenting (CS) with predilatation
Number of subjects: 72
Study: 34510634

Group type: EXPERIMENTAL
Intervention: Sonographers with varying levels of expertise (3 general practitioners, 3 credentialed veterinary technicians, 3 board‐certified specialists) performing abdominal ultrasound examinations
Number of subjects: 4

Group type: COMPARATOR
Intervention: General practitioners
Number of subjects: 4
Study: 33377702

Group type: EXPERIMENTAL
Intervention: Transurethral enucleation and resection of the prostate (TUERP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study: 32726422

Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV vaccine (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV vaccine (12-month booster dose)
Number of subjects: 0
Study: 33976335

Group type: EXPERIMENTAL
Intervention: Polymorphic SSR loci identified from whole-genome sequences of spinach accessions.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Validation of SSR loci.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis using SSR allele score data.
Number of subjects: 48
Study: 32641736

Group type: EXPERIMENTAL
Intervention: High levels of pre-radiotherapy PLT and NE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of post-radiotherapy PLT and NE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both low levels of PLT and NE
Number of subjects: 0
Study: 36097401

Group type: EXPERIMENTAL
Intervention: Jacobson's relaxation technique (JRT)
Number of subjects: 312
Study: 32317658

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 72
Study: 36278483

Group type: COMPARATOR
Intervention: DEN-181 (medium dose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: DEN-181 (high dose)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: DEN-181 (low/medium doses)
Number of subjects: 17
Study: 33905738

Group type: EXPERIMENTAL
Intervention: Medication reconciliation via a patient portal
Number of subjects: 499

Group type: COMPARATOR
Intervention: Medication reconciliation by a pharmacy technician (usual care)
Number of subjects: 499
Study: 32505861

Group type: EXPERIMENTAL
Intervention: Chemotherapy + goserelin (C + G)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Chemotherapy only (C)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Both treatment groups (C±G)
Number of subjects: 227
Study: 35245672

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Steaming protocol
Number of subjects: 45
Study: 33632742

Group type: EXPERIMENTAL
Intervention: ATG/GCSF
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ATG/GCSF responders
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 15
Study: 32321353

Group type: EXPERIMENTAL
Intervention: Naturalistic Developmental Behavioral Intervention (NDBI)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Community treatment as usual (Control)
Number of subjects: 67
Study: 33292787

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including mHealth technology, under-desk pedal machine, and management consultation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study: 34697951

Group type: EXPERIMENTAL
Intervention: Distal approach (DA) for local corticosteroid injection (LCI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Proximal approach (PA) for local corticosteroid injection (LCI)
Number of subjects: 60
Study: 33106117

Group type: EXPERIMENTAL
Intervention: Surgery, chemotherapy, and molecularly targeted agents (bevacizumab and PARP inhibitors)
Number of subjects: 5200

Group type: EXPERIMENTAL
Intervention: BRCA testing
Number of subjects: 5200
Study: 35044844

Group type: EXPERIMENTAL
Intervention: Intranasal orexin A (500 nmol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intranasal orexin A
Number of subjects: 10
Study: 32894278

Group type: EXPERIMENTAL
Intervention: Miltefosine and placebo (M + P)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Miltefosine and topical GM‐CSF (M + GM)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Pentavalent antimony (Sbv)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sbv
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: M + P
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: M + GM
Number of subjects: 133
Study: 34853404

Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement with 600 mA amplitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement with 700 mA amplitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement with 800 mA amplitude
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right hippocampal E-field
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximal right hippocampal E-field associated with cognitive safety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whole-brain ratio of E-field strength per unit of stimulation current
Number of subjects: 0
Study: 35843520

Group type: COMPARATOR
Intervention: Tralokinumab monotherapy (ECZTRA 1 + 2)
Number of subjects: 1976

Group type: COMPARATOR
Intervention: Tralokinumab plus optional TCS (ECZTRA 3)
Number of subjects: 1976

Group type: COMPARATOR
Intervention: Tralokinumab (both ECZTRA 1 + 2 and ECZTRA 3)
Number of subjects: 1976

Group type: COMPARATOR
Intervention: Tralokinumab (both ECZTRA 1 + 2)
Number of subjects: 1976
Study: 35403380

Group type: EXPERIMENTAL
Intervention: Azvudine and symptomatic treatment (FNC group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard antiviral and symptomatic treatment (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FNC group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 36188376

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS) over the left lip region of the primary motor cortex (M1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 24
Study: 32393732

Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide and dexamethasone (VRd)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 460
Study: 33420509

Group type: EXPERIMENTAL
Intervention: T-wave abnormalities (TWA) present
Number of subjects: 8176
Study: 35395075

Group type: EXPERIMENTAL
Intervention: Clear aligners (CA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fixed appliances (FA)
Number of subjects: 44
Study: 33466462

Group type: EXPERIMENTAL
Intervention: High-Protein Meal Replacement (HP-MR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 43
Study: 32702878

Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT) using a helmet-type device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 60
Study: 34313686

Group type: EXPERIMENTAL
Intervention: 7-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Number of subjects: 272

Group type: COMPARATOR
Intervention: 14-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Number of subjects: 272
Study: 33157425

Group type: EXPERIMENTAL
Intervention: 3 mg fast-release melatonin
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 34793970

Group type: EXPERIMENTAL
Intervention: Office Suppression Test (3-step procedure to grade suppression on a 4-point scale)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Office Suppression Test (in subgroup of untreated children)
Number of subjects: 57
Study: 33138682

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo version (PTSST)
Number of subjects: 40
Study: 34431517

Group type: EXPERIMENTAL
Intervention: Arousal reappraisal intervention
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 610
Study: 34487412

Group type: EXPERIMENTAL
Intervention: 400 mg rifaximin 3 times/d plus 30-45 mL lactulose 3 times/d
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactulose alone (control group)
Number of subjects: 100
Study: 35697438

Group type: EXPERIMENTAL
Intervention: Standard clinical management based on NEWS2 scoring plus PCT‐guided risk assessment
Number of subjects: 7676

Group type: COMPARATOR
Intervention: Standard clinical management based on NEWS2 scoring alone
Number of subjects: 7676
Study: 33992852

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 1789
Study: 32972965

Group type: EXPERIMENTAL
Intervention: Home-based newborn care by Shishu Rakshak (SR)
Number of subjects: 19373

Group type: COMPARATOR
Intervention: Home-based newborn care by Anganwadi Workers (AWW)
Number of subjects: 19373

Group type: COMPARATOR
Intervention: Control group (routine health services)
Number of subjects: 19373
Study: 33567859

Group type: EXPERIMENTAL
Intervention: 1% high-molecular-weight hyaluronic acid (1 mL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1% low-molecular-weight hyaluronate (1 mL)
Number of subjects: 56
Study: 32460220

Group type: EXPERIMENTAL
Intervention: Heterogeneous group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Homogeneous group
Number of subjects: 42
Study: 35993588

Group type: EXPERIMENTAL
Intervention: Remin Pro®
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GC Tooth mousse™
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sodium fluoride gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 34587974

Group type: EXPERIMENTAL
Intervention: ART-96W
Number of subjects: 229

Group type: COMPARATOR
Intervention: ART-Def
Number of subjects: 229
Study: 32138344

Group type: EXPERIMENTAL
Intervention: 3 g/day oat beta-glucans
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 33990147

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) after curative resection of colon cancer
Number of subjects: 50996
Study: 35948382

Group type: EXPERIMENTAL
Intervention: 40 mg of prednisolone for 10 days
Number of subjects: 116

Group type: COMPARATOR
Intervention: Matching placebo treatment
Number of subjects: 116
Study: 33938826

Group type: EXPERIMENTAL
Intervention: Combined ethamsylate and TXA group (n = 42)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TXA group (n = 42)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 126
Study: 32537812

Group type: EXPERIMENTAL
Intervention: Clinical pharmacy care and pharmacist-led counselling program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 0
Study: 35387919

Group type: EXPERIMENTAL
Intervention: Paprika xanthophylls supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no paprika xanthophylls)
Number of subjects: 0
Study: 33971105

Group type: EXPERIMENTAL
Intervention: Reproductive group during ischemic phase
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y hormone in the ischemic phase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Postmenopausal group
Number of subjects: 28
Study: 33324394

Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Secukinumab 75mg (escalated to 150mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 34534664

Group type: EXPERIMENTAL
Intervention: HEART Camp intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 204
Study: 33275842

Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 127
Study: 35749352

Group type: EXPERIMENTAL
Intervention: Treatment cream (inert unscented lotion) administered by a provider
Number of subjects: 187
Study: 32611117

Group type: EXPERIMENTAL
Intervention: Navigation strategies based on minimization of individual paths or travel times.
Number of subjects: 0
Study: 34882581

Group type: EXPERIMENTAL
Intervention: Neoadjuvant vaccination with GBM6-AD lysate and poly-ICLC
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Adjuvant vaccines (given to all patients)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (arm 2, no neoadjuvant vaccination)
Number of subjects: 17
Study: 32779711

Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 69
Study: 35616047

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg methadone (MET)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 7.5 μg/kg dexmedetomidine (D7)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 μg/kg dexmedetomidine (D10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 7.5 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM7)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM10)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atipamezole (RT30)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methadone (MET)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (7.5 µg/kg)
Number of subjects: 10
Study: 32051972

Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) mouthwash
Number of subjects: 33
Study: 35954942

Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training, 4 unilateral 2-minute contractions at 30% of maximal voluntary contraction, 5 days per week for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sedentary control group (CON)
Number of subjects: 22
Study: 33681993

Group type: EXPERIMENTAL
Intervention: Rhinovirus A16 (3 different doses)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4